TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT06540833: A Multicenter, Randomized, Double-blind, Placebo-controlled, Flexible-dose Study to Assess the Efficacy, Safety, and Tolerability of ITI 1284 in Patients With Psychosis Associated With Alzheimer's Disease

Sponsor: Intra-Cellular Therapies, Inc. · Phase: PHASE2 · Area: CNS_NEUROLOGY · Target Enrollment: 370 pts

Competing Trials Overlap

11 Active Trials

Excess Burn Exposure

$9,079,200

Rescue Site Savings

+$5,975,200

Unlock Full NCT06540833 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06540833 Rescue Dossier →